Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (20)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Alhadi, H.A.
Right arrow Articles by Fox, K.A.A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alhadi, H.A.
Right arrow Articles by Fox, K.A.A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Q J Med 2004; 97: 187-198
QJM vol. 97 no. 4 (c) Association of Physicians 2004; all rights reserved.

Review

Do we need additional markers of myocyte necrosis: the potential value of heart fatty-acid-binding protein

H.A. Alhadi and K.A.A. Fox

From the Cardiovascular Research Unit, Centre for Cardiovascular Science, University of Edinburgh, Royal Infirmary of Edinburgh, Edinburgh, UK

Heart fatty-acid-binding protein (FABP) is a small cytosolic protein that is abundant in the heart and has low concentrations in the blood and in tissues outside the heart. It appears in the blood as early as 1.5 h after onset of symptoms of infarction, peaks around 6 h and returns to baseline values in 24 h. These features of H-FABP make it an excellent potential candidate for the detection of acute myocardial infarction (AMI). We review the strengths and weaknesses of H-FABP as a clinically applicable marker of myocyte necrosis in the context of acute coronary syndromes.

Address correspondence to Professor K.A.A. Fox, Professor of Cardiology, University of Edinburgh, Chancellor's Building, 49 Little France Crescent, Edinburgh EH16 4SB. e-mail: k.a.a.fox{at}ed.ac.uk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Eur Respir JHome page
S. E. Orfanos and S. Zakynthinos
Heart biomarkers as prognostic tools for chronic thromboembolic pulmonary hypertension: a step forward by the fatty acid-binding protein
Eur. Respir. J., May 1, 2008; 31(5): 915 - 917.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
M. Lankeit, C. Dellas, A. Panzenbock, N. Skoro-Sajer, D. Bonderman, M. Olschewski, K. Schafer, M. Puls, S. Konstantinides, and I. M. Lang
Heart-type fatty acid-binding protein for risk assessment of chronic thromboembolic pulmonary hypertension
Eur. Respir. J., May 1, 2008; 31(5): 1024 - 1029.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
M. Puls, C. Dellas, M. Lankeit, M. Olschewski, L. Binder, A. Geibel, C. Reiner, K. Schafer, G. Hasenfuss, and S. Konstantinides
Heart-type fatty acid-binding protein permits early risk stratification of pulmonary embolism
Eur. Heart J., January 2, 2007; 28(2): 224 - 229.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.